ARRY Financial Facts
Cost of revenue: 8.85MResearch and development for proprietary programs: 46.56M
See Full Income Statement
Other long-term liabilities: 662K
Total liabilities and stockholders' deficit: 166.86M
See Full Balance Sheet
Array BioPharma, Inc. (ARRY) Earnings
|
Expand Research on ARRY
| Next EPS Date | 11/5/26 | EPS Growth Rate | -70.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +94.5% | Revenue Growth Rate | -14.2% |
| Average % Move 1-Wk after EPS | -6.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/5/26  |
Q326 | N/A | $0.09 | N/A | N/A | $337.54M | = | N/A | N/A | ||
| 8/5/26 |
Q226 | $0.24 | $0.12 | +$0.12 | $342.06M | $317.88M | = |  | | Details | |
| 5/6/26 | Q126 | $0.06 | -$0.05 | +$0.11 | $223.4M | $210.34M | = | | | Details | |
| 2/25/26 | Q425 | -$0.01 | $0.00 | -$0.01 | $226M | $212.19M | = | | | Details | |
| 11/5/25 | Q325 | $0.30 | $0.19 | +$0.11 | $393.49M | $305.93M | = | | | Details | |
| 8/7/25 | Q225 | $0.25 | $0.19 | +$0.06 | $362.2M | $291.41M | = | | | Details | |
| 5/6/25 | Q125 | $0.13 | $0.07 | +$0.06 | $302.4M | $256.58M | = | | | Details | |
| 2/27/25 | Q424 | $0.16 | $0.18 | -$0.02 | $275.23M | $272.51M | = | | | Details |
